New immunosuppressant class not without serious concerns.
Thompson
Cheryl A
CA
D000152:Acne Vulgaris / Q000139:chemically induced; D000068338:Everolimus; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016377:Organ Transplantation; D020123:Sirolimus / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus